Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material
04 4월 2024 - 5:17AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
SCHEDULE 14A
(Rule 14a-101)
INFORMATION REQUIRED IN PROXY STATEMENT
SCHEDULE 14A INFORMATION
Proxy Statement Pursuant to Section 14(a) of the
Securities Exchange Act of 1934
(Amendment No. )
Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐
Check the appropriate box:
|
☐
|
Preliminary Proxy Statement
|
| |
|
|
☐
|
Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
|
| |
|
|
☐
|
Definitive Proxy Statement
|
| |
|
|
☒
|
Definitive Additional Materials
|
| |
|
|
☐
|
Soliciting Material under §240.14a-12
|
Zevra Therapeutics, Inc.
(Name of Registrant as Specified in its Charter)
(Name of Person(s) Filing Proxy Statement, if Other Than the Registrant)
Payment of Filing Fee (Check all boxes that apply):
|
☒
|
No fee required
|
| |
|
|
☐
|
Fee paid previously with preliminary materials
|
| |
|
|
☐
|
Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11
|
KemPharm (NASDAQ:KMPH)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
KemPharm (NASDAQ:KMPH)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024
